Travere Therapeutics Competitors and Similar CompaniesClear all

Travere Therapeutics's competitors and similar companies include Genexine, JCR Pharmaceuticals, Bath ASU and Kamada Pharmaceuticals.

	Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.	Genexine Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics.	JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.	Bath ASU Bath ASU (also known as Qualasept) is a pharmaceutical specials manufacturer.	Kamada Pharmaceuticals Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.
Founding Date	Founding Date 2011	Founding Date 1999	Founding Date 1975	Founding Date 2006	Founding Date 1990
Type	Type Public	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy
Locations	Locations San Diego, US HQ Dublin, IE	Locations Seongnam-si, KR HQ New York, US	Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP	Locations Corsham, GB HQ	Locations Rehovot, IL HQ Beit Kama, IL
Employees	Employees 46293% increase	Employees 86	Employees 934	Employees 96	Employees 42011% increase
Valuation ($)	Valuation ($) 1.4 b	Valuation ($) N/A	Valuation ($) 533.9 m	Valuation ($) N/A	Valuation ($) 317 m
Financial
Revenue (est.)	Revenue (est.) $233.2m (FY, 2024)	Revenue (est.) ₩4.4b (FY, 2023)	Revenue (est.) ¥42.9b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) $161m (FY, 2024)
Cost of goods	Cost of goods $7.7m (FY, 2024)	Cost of goods ₩583.6m (FY, 2023)	Cost of goods ¥8.4b (FY, 2024)	Cost of goods N/A	Cost of goods $63.9m (FY, 2024)
Gross profit	Gross profit $225.4m (FY, 2024)	Gross profit ₩6b (FY, 2023)	Gross profit ¥34.4b (FY, 2024)	Gross profit N/A	Gross profit $97.2m (FY, 2024)
Net income	Net income ($321.5m) (FY, 2024)	Net income (₩66.9b) (FY, 2023)	Net income ¥5.5b (FY, 2024)	Net income N/A	Net income $14.5m (FY, 2024)
Funding
Total funding raised	Total funding raised $ 25m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 90m